Details of the Drug
General Information of Drug (ID: DMC3DVB)
| Drug Name |
Figitumumab
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
AC1OCENC; (2R)-3-[(4S,6R,7R,10S)-4-[(E,2R)-4-[(2S,2'S,4R,4aS,6R,8aR)-4-hydroxy-2-[(1S,3S)-1-hydroxy-3-[(6S,9R,10S)-9-methyl-5,11-dioxaspiro[5.5]undecan-10-yl]butyl]-3-methylidenespiro[4a,7,8,8a-tetrahydro-4H-pyrano[3,2-b]pyran-6,5'-oxolane]-2'-yl]but-3-en-2-yl]-7-hydroxy-2-methyl-5,11-dioxaspiro[5.5]undec-1-en-10-yl]-2-hydroxy-2-methylpropanoic acid
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Monoclonal antibody
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Malignant adrenal gland cancer | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | 2D11 | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||

